Market Research Reports and Industry Reports

LARGE CAP PHARMA US & EU OUTLOOK 2016: MAXIMIZING THEIR STRENGTH ON FEWER THERAPY CLASS, PERSONALIZED MEDICINE, NOVEL TARGET AND BIOSIMILARS FOR FUTURE GROWTH

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology. Bristol-Myerss with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1 drug. Along with Bristol, theres Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field.

The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimers disease, Parkinsons, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain). Celgene (CELG) keeps capitalizing on its strength in hematology and operational excellence to build global standards of care in the segments of Oncology and Inflammation & Immunology (I&I).

Gilead, a prominent player in Hepatitis C therapy areas is looking to expand its learning in Liver disease for another high unmet need of Nonalcoholic Steatohepatitis (NASH), while its Oncolgy segment failed to make any major impact other than approved drug Zydelig. First in-class mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors continue to get attraction by large cap pharma companies. Biotech and pharmaceutical companies pursue targeted and specialized therapies more than 25% (45 new drugs approval vs. 44 in 2014) of drugs approved by FDA in 2015 are Personalized Medicines. Global Biopharmaceutical Outlook 2016-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.
Figure 1
Amgen
IMPACT OF BLINATUMOMAB TREATMENT IN MRD+ ALL PTS
Figure 1 :Novo Nordisk KEY FEATURES OF COMPOUNDS IN PHASE 1 VELOPMENT FOR OBESITY








List Of Tables

KEY MILESTONES (AMGN)
Data Block ( AMGN)
KEY MILESTONES (CELG)
Data Block ( CELG)
Table 1 : CELGENE -
RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RECENTLY APPROVED DATA COMPARISON
Data Block ( BIIB)
KEY MILESTONES (BIIB)
ANNEXURE: Biogen Idec
MULTIPLE SCLEROSIS INJECTABLE DRUGS DATA COMPARISON
Table 1 :Gilead Sciences
DEVELOPMENT PIPELINE
Table 2 :Gilead Sciences
DATA FROM ASTRAL -1 STUDY
Table 3 :Gilead Sciences
DATA FROM ASTRAL-4 STUDY
Key Milestones ( GILD)
Data Block ( GSK)
KEY MILESTONES (GSK)
Data Block Merck & Co. ( MRK)
Table 1 :Merck
KEYTRUDA: LIST OF ON-GOING COMBINATION STUDIES
Table 2 :Merck
DATA FROM C-CREST 1 & 2 PART A STUDYKEY MILESTONES (MRK)
Data Block : Merck KGaA
MILESTONE TABLE (MRK.EU)
Data Block ( NVS)
Table 1 :Novartis
DATA FROM PHIII STUDY OF BUPARLISIB IN BREAST CANCER (BELLE-2)
Table 2 :Novartis
EFFICACY DATA OF LCZ696 IN PARADIGM-HF
Table 3 :Novartis
SANDOZ BIOSIMILAR PIPELINE STATUS
KEY MILESTONES (NVS)
Data Block (NOVOB)
Table 1 :Novo Nordisk
SELECTED LONG-ACTING rFVIII AND rFIX PRODUCTS
KEY MILESTONES (NOVOB)

List Of Figures

Figure 1
Amgen
IMPACT OF BLINATUMOMAB TREATMENT IN MRD+ ALL PTS
Figure 1 :Novo Nordisk KEY FEATURES OF COMPOUNDS IN PHASE 1 VELOPMENT FOR OBESITY








United States Large-Format Inkjet Printer Market Report 2016

Notes:Sales, means the sales volume of Large-Format Inkjet PrinterRevenue, means the sales value of Large-Format Inkjet PrinterThis report studies sales (consumption) of Large-Format Inkjet Printer in United States market, focuses

USD 3800View Report

Europe Large Power Transformers Market Report 2016

Notes:Sales, means the sales volume of Large Power TransformersRevenue, means the sales value of Large Power TransformersThis report studies sales (consumption) of Large Power Transformers in Europe market, especially in

USD 3900View Report

United States Large Bore Vascular Closure Devices Market Report 2016

Notes:Sales, means the sales volume of Large Bore Vascular Closure DevicesRevenue, means the sales value of Large Bore Vascular Closure DevicesThis report studies sales (consumption) of Large Bore Vascular Closure

USD 3800View Report

Puracap Pharmaceutical LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

PuraCap Pharmaceutical LLC (PuraCap) is a pharmaceutical company that manufactures prescription, private label and generic products. The company also provides over the counter soft gels and oral solid dosage healthcare

USD 250View Report

Global Pharma US & EU Outlook 2015 : First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisitionIn the recent years several new therapies have been approved

USD 2000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprisewide Licence    $ 6000
$ 2000

Reports Details

Published Date : Mar 2016
No. of Pages :97
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment